Dr. Berta Strulovici received her Ph.D. from the Weizmann Institute of Science in Rehovot, Israel. She then conducted postdoctoral research under the guidance of Professor Robert J. Lefkowitz at the Howard Hughes Medical Institute of the Duke University Medical School in Durham, NC, USA. Berta has a track record in building and leading outstanding, productive teams, while integrating innovative processes into seamless, successful enterprises in start-up and Big Pharma environments. At Merck Sharpe and Dohme in North Wales, PA, Berta was Vice President of Basic Research in charge of building a state-of-the-art Center of Excellence for early drug discovery for Merck Worldwide. She was involved in the discovery of lead compounds that are currently in clinical trials for various diseases. In 2011, Berta joined a new start up biotech, iPierian, in the Bay Area as Founding Chief Technology Officer. At iPierian, she focused the company on applying induced Pluripotent Stem Cell technology to drug discovery for neurodegenerative diseases. Most recently, Berta undertook a new role as Director of the National Center for Personalized Medicine in Israel, located at the Weizmann Institute of Science. The Center will be applying novel technologies in genomics, proteomics and High Throughput Screening to enable and advance Personalized Medicine in Israel.
Shmulik earned his Ph.D here at the Weizmann Institute under the mentorship of Prof. Alexander Tsafriri in the department of Biological Regulation, followed by a postdoc fellowship at Massachusetts Institute of Technology with Prof. Ernest Fraenkel in the dept. of Biological Engineering. His research there focused on transcriptional regulation of type II diabetes mellitus. Before joining the G-INCPM, Shmulik managed the Genomics wet lab at the BioMicro Center – The MIT Genomics core facility.
Dr. Haim Barr completed his Ph.D. studies in the Technion – Israel Institute of Technology in 2001 and then pursued a career in biotechnology for 11 years. Coming from academic studies in the fields of ubiquitin and phosphatase biology, Haim initially was a research group leader and then lead drug discovery efforts in Proteologics Ltd. In those years, Proteologics successfully transferred from target to small molecule discovery with a unique and automated integration of in vitro ubiquitination assays which has become the backbone of the company’s activities. Subsequently, Haim joined BiolineRx Ltd. where he specialized in recruitment and management of early-phase projects from Israeli and international academic labs for translation into industrial/clinical development. In addition to Haim’s basic science and automation skills, he has been involved in bio-industrial business development for several years, where he served as in-licensing manager in BiolineRx.
Dr. Yishai Levin is a mass spectrometry expert, specializing in protein analysis. He completed his Ph.D. at the University of Cambridge, UK, where he conducted research relating to biomarker discovery for neuropsychiatric disorders. Yishai has been running the Proteomics Platform for two years, working with dozens of investigators on a wide variety of research projects, all relating to quantitative proteomic analysis.
Danny Ben-Avraham received his Ph.D. from the Hebrew University. After completion of his degree, he spent three years as a research fellow in the institute for Aging Research at the Albert Einstein College of Medicine (NY) where his research focus was the human genome and epigenome and its impact on aging and longevity. Prior to joining the Center, Danny worked at Proteologics Ltd., a biopharmaceutical company that specializes in the ubiquitin system, as the Head of Bio & Cheminformatics group. In this role, he built expert systems, used statistical methods and advanced techniques in computer-aided drug design such as QSAR, Pharmachophores, Docking and homology modeling. Previously, he worked at Quark Biotech Inc., as an Advanced Annotation team leader in the Bioinformatics group, and at Comverse Technology, Inc. as a programmer and activity leader.
Mr. Sharon Dahan holds a Bachelor of Technology (B.Tech.) in Civil Engineering and various Software and System Engineering certificates. Sharon is an Information Technology and Operations Executive experienced in implementation of innovative technology and operational processes that enable enterprise scalability with a focus on efficient and effective resource investment. Prior to joining the Center he worked for ten years in an international company dbMotion, holding the role of CIO. He enabled the company to become a global player and has played a major role in the growth of the company. dbMotion is an innovative provider of medical informatics. The dbMotion™ Solution facilitates Interoperability and Health Information Exchange (HIE) . Sharon is an expert in many of the fields needed for the development and implementation of the Information Technology Platform in order to create the IT vision and long term strategy for the G-INCPM Center and to build a strong Information Technology capability to handle BIG DATA with the volume and complexity generated.
completed his Ph.D studies in Organic Chemistry at Colorado State University, Colorado, USA in 1988, after which he joined Pfizer Pharmaceuticals as a Medicinal Chemist in Groton, Connecticut. Since joining Pfizer, he has worked in multiple therapeutic areas, including Cardiovascular, Metabolic Diseases, Osteoporosis, Frailty, Inflammation, and Immunology. He has made significant contributions to the discovery of multiple compounds that entered Human clinical trials, as well as working on early stage projects validating HTS hits, and progressing these molecules to chemical probes, and ultimately to clinical candidates. Currently, Dr. Lefker is a visiting scientist in the INCPM, and is working closely with Dr. Barr’s HTS group until he returns to Pfizer in the fall of 2017. Dr. Lefker is an author of 45 scientific publications and an inventor on over 60 patents and patent applications.